PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
45.56%
Operating income growth above 1.5x TRVN's 14.24%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.89%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
30.77%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.77%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth above 1.5x TRVN's 37.31%. David Dodd would confirm a clear edge in underlying cash generation.
98.49%
FCF growth above 1.5x TRVN's 37.31%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
10Y OCF/share CAGR above 1.5x TRVN's 49.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
94.54%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
94.54%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
-8.80%
Negative 10Y net income/share CAGR while TRVN is at 60.68%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-8.80%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-273.39%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-273.39%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-273.39%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.63%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.22%
We have some new debt while TRVN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
We cut SG&A while TRVN invests at 10.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.